JPMorgan Chase & Co. Cuts Becton, Dickinson and Company (NYSE:BDX) Price Target to $175.00

Becton, Dickinson and Company (NYSE:BDX) had its price objective cut by JPMorgan Chase & Co. from $190.00 to $175.00 in a report issued on Tuesday, Marketbeat Ratings reports. They currently have a neutral rating on the medical instruments supplier’s stock.

Several other equities research analysts have also recently weighed in on BDX. Bank of America increased their price target on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a research report on Monday, January 5th. Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Royal Bank Of Canada decreased their target price on Becton, Dickinson and Company from $210.00 to $172.00 and set a “sector perform” rating for the company in a report on Monday. Wells Fargo & Company cut their price target on shares of Becton, Dickinson and Company from $184.00 to $157.00 and set an “equal weight” rating on the stock in a report on Tuesday. Finally, Stifel Nicolaus upped their price objective on shares of Becton, Dickinson and Company from $210.00 to $215.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Five analysts have rated the stock with a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $195.46.

Becton, Dickinson and Company Stock Down 1.5%

BDX opened at $177.93 on Tuesday. Becton, Dickinson and Company has a 12 month low of $127.59 and a 12 month high of $185.02. The company has a current ratio of 1.05, a quick ratio of 0.64 and a debt-to-equity ratio of 0.67. The business’s 50-day moving average price is $199.18 and its 200-day moving average price is $192.25. The company has a market cap of $50.66 billion, a P/E ratio of 29.03, a P/E/G ratio of 2.38 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Monday, February 9th. The medical instruments supplier reported $2.91 EPS for the quarter, topping analysts’ consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a return on equity of 15.76% and a net margin of 8.01%.The business had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.15 billion. During the same period in the previous year, the firm earned $3.43 EPS. The business’s quarterly revenue was up 1.6% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. On average, equities analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its board has initiated a stock buyback plan on Tuesday, January 27th that allows the company to buyback $10.00 million in shares. This buyback authorization allows the medical instruments supplier to purchase up to 0% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 31st. Shareholders of record on Tuesday, March 10th will be paid a dividend of $1.05 per share. The ex-dividend date of this dividend is Tuesday, March 10th. This represents a $4.20 dividend on an annualized basis and a dividend yield of 2.4%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 68.52%.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, EVP Michael David Garrison sold 1,610 shares of the firm’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $207.46, for a total transaction of $334,010.60. Following the completion of the transaction, the executive vice president owned 12,095 shares of the company’s stock, valued at $2,509,228.70. This trade represents a 11.75% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 2,463 shares of company stock valued at $501,530. Corporate insiders own 0.40% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. SOA Wealth Advisors LLC. increased its holdings in Becton, Dickinson and Company by 256.8% in the 3rd quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier’s stock worth $25,000 after buying an additional 95 shares in the last quarter. Activest Wealth Management boosted its holdings in shares of Becton, Dickinson and Company by 285.3% during the 3rd quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier’s stock valued at $25,000 after acquiring an additional 97 shares during the last quarter. Imprint Wealth LLC bought a new stake in shares of Becton, Dickinson and Company in the third quarter worth approximately $25,000. Steph & Co. lifted its position in Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier’s stock valued at $26,000 after purchasing an additional 65 shares during the period. Finally, Bell Investment Advisors Inc lifted its position in Becton, Dickinson and Company by 474.1% during the second quarter. Bell Investment Advisors Inc now owns 155 shares of the medical instruments supplier’s stock valued at $27,000 after purchasing an additional 128 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Becton, Dickinson and Company News Roundup

Here are the key news stories impacting Becton, Dickinson and Company this week:

• Positive Sentiment: Jefferies upgraded BDX to a Buy, providing direct bullish pressure that can support the stock as investors reframe valuation vs. the new pure‑play MedTech focus. Becton Dickinson (BDX) Gets a Buy from Jefferies
• Positive Sentiment: BD completed its Biosciences & Diagnostics spin‑off and merged that business with Waters, locking in roughly $4B in proceeds and accelerating a pivot to a pure‑play MedTech company — a structural catalyst for longer‑term re‑rating. BD Merges Biosciences & Diagnostics Business With Waters
• Positive Sentiment: Q4 results and commentary showed a sales surprise and management highlighted portfolio reshaping and product investments that offset tariff headwinds — supportive for medium‑term margin recovery expectations. BDX Q4 Deep Dive: Portfolio Reshaping and Product Investments Offset Tariff Headwinds
• Positive Sentiment: High‑profile bullish commentary (e.g., Jim Cramer) is adding retail investor interest and narrative support for the “new company” story after the restructuring. Jim Cramer on Becton, Dickinson: “I kind of really like the new company”
• Neutral Sentiment: TD Cowen nudged its price target to $189 from $183 but kept a Hold rating — a modest signal that sentiment is mixed, offering limited near‑term directional impact. TD Cowen Adjusts Becton, Dickinson and Company PT to $189 from $183; Maintains Hold Rating
• Negative Sentiment: Multiple large banks issued pessimistic forecasts or analyst downgrades (JPMorgan, Wells Fargo), increasing selling pressure and contributing to the morning gap down. JPMorgan Chase & Co. Issues Pessimistic Forecast for Becton, Dickinson and Company (NYSE:BDX) Stock Price
• Negative Sentiment: Wells Fargo’s pessimistic outlook added to the analyst sell‑side momentum and volatility pressure. Wells Fargo & Company Issues Pessimistic Forecast for Becton, Dickinson and Company (NYSE:BDX) Stock Price
• Negative Sentiment: Citigroup trimmed its price target (publication notes a lower target), and at least one downgrade produced an early‑session gap down — clear near‑term negatives despite the firm’s longer‑term cash/reshaping positives. Citigroup Lowers Becton, Dickinson and Company (NYSE:BDX) Price Target to $232.00
• Negative Sentiment: Coverage notes that BDX shares gapped down on an analyst downgrade, signalling immediate selling pressure and higher intraday volume as investors digest mixed signals. Becton, Dickinson and Company (NYSE:BDX) Shares Gap Down on Analyst Downgrade

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.